1型糖尿病患者服用益生菌补充剂:加拿大一项随机对照试验的研究方案
Carol Huang1,2, Elizabeth Rosolowsky3,4, Munier A Nour5
1Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
BMJ open
|May 31, 2025
概括
在1型糖尿病 (T1D) 中补充益生菌纤维可能会降低低血糖并保持β细胞功能. 这项研究研究了在T1D患者中对血糖控制和肠道健康的益生菌影响.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 1型糖尿病 (T1D) 是由自身免疫β细胞破坏引起的,需要胰岛素治疗,并带来低血糖的风险.
- 肠道失调和肠道透性 (IP) 的增加与T1D的失糖症有关.
- 益生菌纤维有潜力减轻失生症,减少IP,改善血糖控制,这表明它具有治疗作用.
研究的目的:
- 检查益生菌补充剂对T1D患者低血糖频率和血糖变异性的影响.
- 评估肠道微生物群,肠道透性和残留β细胞功能的益生菌诱导的变化.
- 评估益生菌对生活质量和T1D中低血糖的恐惧的影响.
主要方法:
- 一个为期6个月的多中心,随机,双盲,安慰剂对照试验,涉及144名T1D患者.
- 参与者接受了益生菌 (富含橄果糖的胰岛素) 或安慰剂 (马尔托德克斯).
- 主要结果:通过持续血糖监测 (CGM) 和日志评估低血糖的频率;次要结果:血糖变异性,C-,IP,微生物组分析.
主要成果:
- 试验数据显示,在患有T1D的儿童中,益生菌纤维降低了低血糖的频率,并增加了Bifidobacterium.
- 益生菌组维持了血清C-水平,表明维护了β细胞功能,与安慰剂组不同.
- 在益生菌组中观察到肠道透性的适度改善.
结论:
- 益生菌补充剂在降低低血糖和保持T1D中的β细胞功能方面显示出有希望.
- 益生菌诱导的微生物和肠道适应可能有助于改善T1D中的血糖控制.
- 需要进一步的研究,以在更大的队列中证实这些发现.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243


